|
1
|
Hauso O, Gustafsson BI, Kidd M, Waldum HL,
Drozdov I, Chan AK and Modlin IM: Neuroendocrine tumor
epidemiology: Contrasting Norway and North America. Cancer.
113:2655–2664. 2008.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Dasari A, Shen C, Halperin D, Zhao B, Zhou
S, Xu Y, Shih T and Yao JC: Trends in the incidence, prevalence,
and survival outcomes in patients with neuroendocrine tumors in the
United States. JAMA Oncol. 3:1335–1342. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Walters SL, Canavan ME, Salazar MC, Resio
BJ, Blasberg JD, Mase V and Boffa DJ: A National study of
surgically managed atypical pulmonary carcinoid tumors. Ann Thorac
Surg. 112:921–927. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG (eds): WHO Classification of Tumours of the Lung,
Pleura, Thymus and Heart. 4th edition. IARC Press, Lyon, 2015.
|
|
5
|
Dong S, Liang J, Zhai W and Yu Z:
Development and validation of an individualized nomogram for
predicting overall survival in patients with typical lung carcinoid
tumors. Am J Clin Oncol. 43:607–614. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Petursdottir A, Sigurdardottir J,
Fridriksson BM, Johnsen A, Isaksson HJ, Hardardottir H, Jonsson S
and Gudbjartsson T: Pulmonary carcinoid tumours: Incidence,
histology, and surgical outcome. A population-based study. Gen
Thorac Cardiovasc Surg. 68:523–529. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Chong CR, Wirth LJ, Nishino M, Chen AB,
Sholl LM, Kulke MH, McNamee CJ, Jänne PA and Johnson BE:
Chemotherapy for locally advanced and metastatic pulmonary
carcinoid tumors. Lung Cancer. 86:241–246. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Baudin E, Caplin M, Garcia-Carbonero R,
Fazio N, Ferolla P, Filosso PL, Frilling A, de Herder WW, Hörsch D,
Knigge U, et al: Lung and thymic carcinoids: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up*. Ann Oncol.
32:439–451. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
National Comprehensive Cancer Network.
Neuroendocrine and Adrenal Tumors. Version 4.2021. 2021. Available
from: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf.
|
|
10
|
Thomas C: Lung Neuroendocrine (carcinoid)
Tumors: Treatment and Prognosis. UpToDate. 2021. Available from:
https://www.uptodate.com/contents/lung-neuroendocrine-carcinoid-tumors-treatment-and-prognosis.
|
|
11
|
Bini A, Brandolini J, Cassanelli N, Davoli
F, Dolci G, Sellitri F and Stella F: Typical and atypical pulmonary
carcinoids: Our institutional experience. Interact Cardiovasc
Thorac Surg. 7:415–418. 2008.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Baudin E, Hayes AR, Scoazec JY, Filosso
PL, Lim E, Kaltsas G, Frilling A, Chen J, Kos-Kudła B, Gorbunova V,
et al: Unmet medical needs in pulmonary neuroendocrine (Carcinoid)
neoplasms. Neuroendocrinology. 108:7–17. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Das S, Al-Toubah T and Strosberg J:
Chemotherapy in neuroendocrine tumors. Cancers (Basel).
13(4872)2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Espinosa-Olarte P, La Salvia A,
Riesco-Martinez MC, Anton-Pascual B and Garcia-Carbonero R:
Chemotherapy in NEN: Still has a role? Rev Endocr Metab Disord.
22:595–614. 2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Filosso PL, Oliaro A, Ruffini E, Bora G,
Lyberis P, Asioli S, Delsedime L, Sandri A and Guerrera F: Outcome
and prognostic factors in bronchial carcinoids: A single-center
experience. J Thorac Oncol. 8:1282–1288. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gosain R, Groman A, Yendamuri SS, Iyer R
and Mukherjee S: Role of adjuvant chemotherapy in pulmonary
carcinoids: An NCDB analysis. Anticancer Res. 39:6835–6842.
2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Westin GF, Alsidawi S, Leventakos K,
Halfdanarson TR and Molina JR: Impact of adjuvant chemotherapy in
non-metastatic node positive bronchial neuroendocrine tumors
(BNET). J Clin Oncol. 35 (Suppl 15)(S8533)2017.
|
|
18
|
He Y, Zhao F, Han Q, Zhou Y and Zhao S:
Prognostic nomogram for predicting long-term cancer-specific
survival in patients with lung carcinoid tumors. BMC Cancer.
21(141)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Vansteenkiste J: Pulmonary carcinoid: A
rare thoracic malignancy, a high need for better defined systemic
therapy. Ann Oncol. 26:1527–1529. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Nussbaum DP, Speicher PJ, Gulack BC,
Hartwig MG, Onaitis MW, D'Amico TA and Berry MF: Defining the role
of adjuvant chemotherapy after lobectomy for typical
bronchopulmonary carcinoid tumors. Ann Thorac Surg. 99:428–434.
2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Melek H, Çetinkaya G, Özer E, Yentürk E,
Sevinç TE, Bayram AS and Gebitekin C: Pathological complete
response after neoadjuvant/induction treatment: Where is its place
in the lung cancer staging system? Eur J Cardiothorac Surg.
56:604–611. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Goldstraw P, Chansky K, Crowley J,
Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P,
Mitchell A, Bolejack V, et al: The IASLC lung cancer staging
project: Proposals for revision of the TNM stage groupings in the
forthcoming (eighth) edition of the TNM Classification for lung
cancer. J Thorac Oncol. 11:39–51. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
National Cancer Institute. Common
Terminology Criteria for Adverse Events (CTCAE) Version 5.0
[Internet]. 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
|
|
24
|
Singh S, Bergsland EK, Card CM, Hope TA,
Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, et
al: Commonwealth neuroendocrine tumour research collaboration and
the North American neuroendocrine tumor society guidelines for the
diagnosis and management of patients with lung neuroendocrine
tumors: An International collaborative endorsement and update of
the 2015 European Neuroendocrine Tumor Society Expert Consensus
Guidelines. J Thorac Oncol. 15:1577–1598. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Girelli L, Casiraghi M, Sandri A, Petrella
F, Galetta D, Gasparri R, Maisonneuve P, Fazio N and Spaggiari L:
Results of surgical resection of locally advanced pulmonary
neuroendocrine tumors. Ann Thorac Surg. 112:405–414.
2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Johnstone TC, Park GY and Lippard SJ:
Understanding and improving platinum anticancer
drugs-Phenanthriplatin. Anticancer Res. 34:471–476. 2014.PubMed/NCBI
|
|
27
|
Rottenberg S, Disler C and Perego P: The
rediscovery of platinum-based cancer therapy. Nat Rev Cancer.
21:37–50. 2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Pulvirenti A, Raj N, Cingarlini S, Pea A,
Tang LH, Luchini C, Chou JF, Grego E, Marinova I, Capanu M, et al:
Platinum-based treatment for well- and poorly differentiated
pancreatic neuroendocrine neoplasms. Pancreas. 50:138–146.
2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Patané AK, Guma G, Rayá M, Rosales A,
Astorino W and Rosenberg M: Pulmonary neuroendocrine carcinoid
tumors : Is there a predictive role to the Ki 67 index? Ann Thorac
Med. 16:274–279. 2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
La Salvia A, Persano I, Siciliani A,
Verrico M, Bassi M, Modica R, Audisio A, Zanata I, Trabalza
Marinucci B, Trevisi E, et al: Prognostic significance of
laterality in lung neuroendocrine tumors. Endocrine. 76:733–746.
2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Naheed S, Holden C, Tanno L, Pattini L,
Pearce NW, Green B, Jaynes E, Cave J, Ottensmeier CH and Pelosi G:
Utility of KI-67 as a prognostic biomarker in pulmonary
neuroendocrine neoplasms: A systematic review and meta-analysis.
BMJ Open. 12(e041961)2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Muscogiuri G, Barrea L, Feola T, Gallo M,
Messina E, Venneri MA, Faggiano A and Colao A: NIKE (Neuroendocrine
Tumors, Innovation inKnowledge, Education) Group. Pancreatic
neuroendocrine neoplasms: Does sex matter? Trends Endocrinol Metab.
31:631–641. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Abdel-Rahman O, Ghosh S and Fazio N:
Sex-based differences in the outcomes of patients with lung
carcinoids. J Comp Eff Res. 11:523–531. 2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Mansoor W, Ferguson S, Ross V and Talbot
D: Diagnostic and management pathways for pulmonary carcinoid
tumours in the United Kingdom: Results from the National lung
neuroendocrine tumour pathway project. Int J Endocrinol.
2020(9287536)2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Melosky B: Advanced typical and atypical
carcinoid tumours of the lung: Management recommendations. Curr
Oncol. 25 (Suppl 1):S86–S93. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Gagliardi I, Tarquini M, Ambrosio MR,
Giannetta E, Borges de Souza P, Gafà R, Carnevale A, Franceschetti
P and Zatelli MC: NEP-Score thresholds predict survival of patients
with bronchial carcinoids. Front Endocrinol (Lausanne).
11(621557)2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Cattoni M, Vallières E, Brown LM,
Sarkeshik AA, Margaritora S, Siciliani A, Filosso PL, Guerrera F,
Imperatori A, Rotolo N, et al: Improvement in TNM staging of
pulmonary neuroendocrine tumors requires histology and regrouping
of tumor size. J Thorac Cardiovasc Surg. 155:405–413.
2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Yi C, Dai J, Song N, Wu C, Zhang L, Zhu Y,
Jiang G, Zhang H and Zhang P: Improvement of pathological staging
system for neuroendocrine tumors of the lung. Ann Transl Med.
9(447)2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Dermawan JKT and Farver CF: The role of
histologic grading and Ki-67 index in predicting outcomes in
pulmonary carcinoid tumors. Am J Surg Pathol. 44:224–231.
2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Moran CA, Lindholm KE, Brunnström H,
Langman G, Jang SJ, Spagnolo D, Chai SM, Laycock A, Falconieri G,
Pizzolitto S, et al: Typical and atypical carcinoid tumors of the
lung: A clinicopathological correlation of 783 cases with emphasis
on histological features. Hum Pathol. 98:98–109. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Chiappetta M, Sperduti I, Ciavarella LP,
Leuzzi G, Bria E, Mucilli F, Lococo F, Filosso P, Ratto G,
Spaggiari L, et al: Prognostic score for survival with pulmonary
carcinoids: The importance of associating clinical with
pathological characteristics. Interact Cardiovasc Thorac Surg.
31:315–323. 2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Georgakopoulou VE, Zygouris E, Nikokiris
C, Damaskos C, Pierrakou A, Garmpis N, Garmpi A, Sklapani P,
Aravantinou A, Trakas N, et al: Predictive indicators of survival
in patients with surgically resected lung carcinoid tumors at a
greek medical center. Cureus. 12(e10300)2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
He H, Guo W, Song P, Liu L, Zhang G, Wang
Y, Qiu B, Tan F, Xue Q and Gao S: Preoperative systemic
immune-inflammation index and prognostic nutritional index predict
prognosis of patients with pulmonary neuroendocrine tumors after
surgical resection. Ann Transl Med. 8(630)2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Caplin ME, Baudin E, Ferolla P, Filosso P,
Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, et
al: Pulmonary neuroendocrine (carcinoid) tumors: European
neuroendocrine tumor society expert consensus and recommendations
for best practice for typical and atypical pulmonary carcinoids.
Ann Oncol. 26:1604–1620. 2015.PubMed/NCBI View Article : Google Scholar
|
